Orbimed Advisors LLC is a healthcare fund management firm that invests in biopharmaceuticals, medical devices, diagnostics, and related healthcare services. The firm has been investing in the healthcare industry globally for the past 20 years. The SEC 13F filings of Orbimed Advisors LLC for the period ended September 30, 2014, showed that its top three holdings are Gilead Sciences, Inc. (NASDAQ:GILD), Biogen Idec Inc (NASDAQ:BIIB), and Bristol-Myers Squibb Co (NYSE:BMY).
The filings indicated that Gilead Sciences, Inc. (NASDAQ:GILD) was the topmost investment of Orbimed Advisors LLC, accounting for investment worth $400.5 million. This is a biotechnology company that specializes in the discovery, development, and commercialization of therapeutics. Gilead Sciences, Inc. (NASDAQ:GILD) strives to cover the unmet medical needs of patients by carrying out research on new treatments. The holdings that own the highest number of shares of the company are Baker Bros. Advisors, which holds 21.5 million shares, and Egerton Capital Limited, representing 5.7 million. (You can see complete list of hedge funds which hold positions on Gilead Sciences, Inc. (NASDAQ:GILD) at the end of third quarter.)
Biogen Idec Inc (NASDAQ:BIIB) emerged the second largest investment of the firm with investment totaling $393.7 million in value. Biogen Idec Inc (NASDAQ:BIIB) is a biotechnology company that discovers, develops, and supplies therapies for people living with neurodegenerative diseases, hematologic conditions and autoimmune disorders. Credit Suisse has downgraded the stock’s price target from $425 to $400, although the firm’s rating on the stock is “outperform”. The top three shareholders of Biogen Idec Inc (NASDAQ:BIIB) are Fidelity Management and Research Company, PRIMECAP Management Company, and T. Rowe Price Associates, Inc.
Bristol-Myers Squibb Co (NYSE:BMY) was the third largest investment of Orbimed Advisors LLC, with investment worth $373.2 million. Bristol-Myers Squibb Co (NYSE:BMY) is an American pharmaceutical company that’s focused on discovering, developing, and delivering medicines to help in the treatment of serious diseases. The company is set to erect a new biologics plant worth $900 million in Ireland in a bid to expand its global market. The third quarter 2014 EPS results for Bristol-Myers Squibb Co (NYSE:BMY) was $0.43, beating The Street estimates of $0.42. Although the earnings beat the estimates, the company’s revenue was down 4% in year over year analysis.
This article has been written by Victor Ochieng.